Based on the aggregated intelligence of 170,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, genetic analysis specialist Illumina (Nasdaq: ILMN) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Illumina's business and see what CAPS investors are saying about the stock right now.

Illumina facts

Headquarters (Founded) San Diego, Calif. (1998)
Market Cap $8.85 billion
Industry Life sciences tools and services
Trailing-12-Month Revenue $902.74 million
Management CEO Jay Flatley (since 1999)
CFO Christian Henry (since 2005)
Return on Equity (Average, Past 3 Years) 9.1%
Cash / Debt $894.3 million / $311.6 million
Competitors Affymetrix (Nasdaq: AFFX)
Beckman Coulter (NYSE: BEC)
General Electric (NYSE: GE)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 93% of the 650 members who have rated Illumina believe the stock will outperform the S&P 500 going forward. These bulls include fundamentalsrock and RedDave.

Earlier this month, fundamentalsrock tapped Illumina as a great way to go for growth: "DNA sequencing is moving into mainstream pharma, and Illumina has the market share and technology. They will dominate for the foreseeable future a fast, fast growing market."

Over the next five years, Illumina is even expected to grow its bottom line at a brisk rate of 27.5% annually. That's faster than listed rivals like Affymetrix (7.5%), Beckman Coulter (8.9%), and General Electric (12.8%).

CAPS member RedDave expands on the outperform case:

Both research and medicine are rapidly becoming dependent on deep sequencing. We are now moving into a time where DNA sequencing is truly as important as a microscope. Illumina has a daunting lead. Even giants can become complacent, and this market has numerous "Davids" looking to pick up some scraps.

Until a very long sequence read technology is developed that can reliably produce single reads of over 10,000 bases, it is Illumina's market to lose. The wide-moat is filling.

What do you think about Illumina, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Illumina is a Motley Fool Stock Advisor selection. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.